NCT07580820 Gait Adaptability in Persons With MS Having Mild Disability
| NCT ID | NCT07580820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hasselt University |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 32 participants in total. It began in 2025-12-05 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system that frequently leads to walking impairment, balance deficits, fatigue, cognitive difficulties, and an increased risk of falls. Importantly, these problems can already be present in the early stages of the disease and may not be adequately captured by standard clinical walking tests, which primarily assess speed or distance. Such tests are often insufficient to reflect the complexity of real-life walking, which requires continuous adaptation to environmental challenges, and attention to internal and external stimuli. Gait adaptability, the ability to modify walking patterns in response to changing and unpredictable demands such as obstacles or sudden perturbations, is critical for safe mobility and fall prevention. Both proactive (anticipatory) and reactive (feedback-driven) gait adaptations are essential for maintaining balance and functional independence. However, gait adaptability and its underlying neural mechanisms remain insufficiently understood in people with MS. This study aims to provide a comprehensive assessment of gait adaptability in people with MS by evaluating both proactive and reactive gait adaptations using objective gait measurements and cortical activity recordings. The findings may contribute to the development of more sensitive outcome measures and inform targeted rehabilitation strategies that better reflect real-life mobility demands. Primary aims: • To investigate the behavioral measures and neural correlates of reactive and proactive gait adaptability in pwMS compared to HC Secondary aims: * To investigate factors related to gait adaptability * To investigate changes in gait adaptability during prolonged walking conditions
Eligibility Criteria
Inclusion Criteria: * Age between 18-65 years, * confirmed diagnosis of definite MS, * relapse free at least 30 days, * Expanded Disability Status Scale (EDSS) score between 0 and 3.5 Exclusion Criteria: * Diagnosed with neurological disease other than MS * cognitive decline that renders the patient incapable of performing tests and questionnaires. * Other neurological, orthopedic, or visual impairments affecting gait
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07580820 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07580820 currently recruiting?
Yes, NCT07580820 is actively recruiting participants. Contact the research team at zuhal.abasiyanik@uhasselt.be for enrollment information.
Where is the NCT07580820 trial being conducted?
This trial is being conducted at Diepenbeek, Belgium.
Who is sponsoring the NCT07580820 clinical trial?
NCT07580820 is sponsored by Hasselt University. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.